Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study.

ABSTRACT:

Objectives

To investigate the clinical characteristics of adverse events (AEs) after COVID-19 vaccination in patients in South Korea.

Design

Data from the Korean Disease Control and Prevention Agency on AEs from 4 COVID-19 vaccines, including AZD1222, BNT162b2, JNJ-78436735, and mRNA-1273, from February 26, 2021, to August 21, 2021, were assessed. The epidemiological characteristics, clinical symptoms, severity, complications, and mortality were descriptively analyzed.

Results

Overall, 36.3 million individuals who completed the COVID-19 vaccination doses during the study period were included, and 153,183 AEs were reported. Most AEs occurred after the first dose (80.6%) and within a day (63.2%) after vaccination. Of the AEs, 95.5% were nonsevere cases; however, 4.5% were severe. Most mild AEs showed a similar frequency across all age groups, but major severe AEs and mortality events increased with age.

Conclusions

Although there were differences in the frequency of occurrence, various adverse reactions were confirmed in using all 4 COVID-19 vaccines, even with the BNT162b2 (Pfizer-BioNTech) vaccine. Caution is needed, and further research should be continuously conducted.

SUBMITTER: Lee DS 

PROVIDER: S-EPMC8904009 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature